Search Results 2571-2580 of 16841 for Epilepsy (Partial Onset)

  1. Pediatrics Clinical Trials - Medical Professionals

    The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer ...

  2. Medical Research & Education - Mayo Clinic News Network

    Gregory Worrell shares how technological innovation is transforming the future of epilepsy care. Latest stories. Mayo Clinic researchers use AI and genetics to ...

  3. Medical Research & Education - Mayo Clinic News Network

    Gregory Worrell shares how technological innovation is transforming the future of epilepsy care. Latest stories. Including AI-derived heart fat measurement ...

  4. Neurology - Clinical trials

    A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

  5. Neurology - Clinical trials - Mayo Clinic

    A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

  6. Neurology - Clinical trials - Mayo Clinic

    A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

  7. Neurology - Clinical trials - Mayo Clinic

    A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

  8. A Trial of the Effectiveness, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4) - Mayo Clinic

    The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of a single oral administration of study drug CP101 for the prevention of ...

  9. VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM - Mayo Clinic

    Prior therapy with gamma knife or other focal ... International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x the ULN.

  10. A Phase 2b, Study Of Linsitinib In Subjects With Active, Moderate To Severe Thyroid Eye Disease (TED) - Mayo Clinic

    Moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life, with onset (as determined by patient records) within 12 ...